Brolucizumab
A single-chain antibody fragment that inhibits vascular endothelial growth factor A, used by injection into the eye to treat wet age-related macular degeneration and diabetic macular edema. Its small molecular size may allow for greater tissue penetration and potentially longer intervals between injections compared to some other anti-VEGF agents. Rare but serious cases of retinal vasculitis have been reported.
Therapeutische Bereiche
Wirkmechanismus
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A single-chain antibody fragment that inhibits vascular endothelial growth factor A, used by injection into the eye to treat wet age-related macular degeneration and diabetic macular edema. Its small molecular size may allow for greater tissue penetration and potentially longer intervals between injections compared to some other anti-VEGF agents. Rare but serious cases of retinal vasculitis have been reported.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Brolucizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3707357. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="brolucizumab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/brolucizumab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/brolucizumab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/brolucizumab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="brolucizumab"></drugfyi-drug>